Skip to main content
. 2022 Aug 25;24:206. doi: 10.1186/s13075-022-02897-5

Table 2.

Different outcomes assessed for the statistical analysis

Outcomes Conditions Data availability
Adverse 1 Treatment with bDMARD within 2 years 118/118
Adverse 2

HAQ > 1 or DAS28 > 5.1 while on csDMARDs

or treatment with bDMARD at 2 years

94/118
Favorable

DAS28 < 3.2 and HAQ ≤ 0.25 and no treatment

with bDMARD at 2 years

93/118